We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Ceramides in Blood Predict Risk of Alzheimer's Disease

By LabMedica International staff writers
Posted on 31 Jul 2012
Print article
High levels of ceramides, a family of lipids, in the blood of a patient may be predictive of developing Alzheimer's disease.

Dr. Mielke PhD, from the Mayo Clinic (Rochester, MN, USA) and her team conducted a study to see whether blood levels of ceramides and sphingomyelins are associated with increased risk of Alzheimer's disease (AD). Previous studies found links between high serum ceramide levels and memory impairment and hippocampal volume loss.

Participants in a longitudinal, population-based study included healthy women 70 to 80 years of age, living in Baltimore, (Maryland, USA). None had dementia at baseline. The women were followed for up to six visits over nine years. Their blood was collected at baseline and at each subsequent visit. Out of 99 women, 27 (27.3%) developed incident dementia. Of these, 18 (66.7%) were diagnosed with probable Alzheimer's disease.

An increased risk of Alzheimer's disease was associated with higher baseline serum ceramides. However, higher levels of sphingomyelins were not linked to increased Alzheimer's disease risk. The team also noted that women in the middle tertile of serum ceramide levels had the highest risk for Alzheimer's versus those in the lowest tertile, with an intermediate increased risk seen among those in the highest tertile.

Michelle M. Mielke said, "The study is small—that's a limitation, and it was a preliminary study. However, given the small sample size, to have hazard ratios that are near 10 was quite striking and we didn't expect to see that at all," said Dr. Mielke. "Pretty much any marker is not going to be associated with a 10-fold risk, so yes, this does need to be replicated in another study, but it suggests to us that plasma or blood ceramide levels are associated with an increased risk of Alzheimer's disease," she said.

According to Valory Pavlik, PhD, of the Alzheimer's disease and memory disorders center at Baylor College of Medicine (Houston, TX, USA) the study findings are noteworthy. Identification of an accurate biomarker to predict Alzheimer's disease that can be obtained with a minimum of cost and inconvenience to a patient, could lead to model focused on preventing or delaying disease onset.

Related Links:
Mayo Clinic
Baylor College of Medicine


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.